Loading stock data…
ZVRA
$10.07-0.10 (-0.98%)
Market ClosedLast close May 1
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Zevra Therapeutics, Inc. in the Healthcare sector is trading at $10.07. The stock is currently 23% below its 52-week high of $13.16, remaining 6.4% above its 200-day moving average. Technical signals show neutral RSI of 56 and bearish MACD signal, explaining why ZVRA maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 56) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$10.07
Potential Upside
65.2%
Whystock Fair Value$16.64
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus9 analysts
Mean target$22.78+126.2%
Range$18.00 – $26.00
Fundamentals
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidat...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$620.11M
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
7.77
Beta
Defensive asset. Lower volatility than the S&P 500.
0.89
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-25.81%
Volume
Today's trading volume
677,988
Recent News
Is GeneDx (WGS) Using Sponsored NPC Testing to Quietly Strengthen Its Data Advantage?
In March 2026, GeneDx Holdings Corp. announced a new Niemann-Pick disease type C Sponsored Genetic Testing Program with Zevra Therapeutics, offering no-cost ExomeDx testing to eligible U.S. patients and contributing de-identified results to its GeneDx Infinity rare disease dataset. This collaboration highlights how sponsored genetic testing and data aggregation can help shorten diagnostic timelines in rare diseases and support more informed treatment decisions. We will now examine how this...
Zevra Ties NPC Testing Push To Valuation Gap And New CFO
Zevra Therapeutics (NasdaqGS:ZVRA) has partnered with GeneDx on a sponsored genetic testing program for Niemann Pick disease type C in the U.S. The program is designed to widen access to genomic testing and support earlier, more accurate NPC diagnosis. Zevra has also appointed Justin Renz as Chief Financial Officer and granted him an equity inducement award aligned with company and stakeholder interests. Zevra Therapeutics focuses on rare diseases, a segment where diagnosis can be slow and...
GeneDx (WGS), Zevra Therapeutics (ZVRA) Partner to Launch Sponsored Genetic Testing Program for NPC
GeneDx Holdings Corp. (NASDAQ:WGS) is one of the most promising stocks under $100 to buy. On March 10, GeneDx and Zevra Therapeutics (NASDAQ:ZVRA) announced a new partnership to launch a sponsored genetic testing program for NPC (Niemann-Pick disease type C). This aims to expand access to GeneDx’s ExomeDx test for patients in the US who […]
Zevra Therapeutics Inc (ZVRA) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Driven by ...
Zevra Therapeutics Inc (ZVRA) reports robust financial performance with significant contributions from MIPLYFFA, despite challenges in operating expenses and market variability.
Is Zevra Therapeutics (ZVRA) Pricing Reflecting Its Strong Multi‑Year Share Price Performance
If you are trying to work out whether Zevra Therapeutics is genuinely good value or just a story stock, it helps to start with what the market has been doing with the share price. Zevra Therapeutics shares last closed at US$10.41, with returns of 16.6% over 7 days, 21.5% over 30 days, 24.8% year to date, 31.4% over 1 year and 128.8% over 3 years, while the 5 year return sits at an 8.8% decline. Recent attention on Zevra Therapeutics has focused on its position in the pharmaceuticals and...